Table 2.
Cross-neutralization using rabbit anti-HAdV-5, rabbit anti-SAdV-24 and IVIG
| Neutralization titer using: |
||||
|---|---|---|---|---|
| Adenovirus species | Adenovirus Isolate | Anti-HAdV-5 (rabbit) | Anti-SAdV-24 (rabbit) | IVIG (human) |
| C | HAdV-5 | 1:81920 | <1/20 | 1/640 |
| E | SAdV-24 | <1:20 | 1:655360 | 1:20 |
| E | SAdV-25.2 | <1:20 | 1:655360 | 1:40 |
| SAdV-26 | 1:20 | 1:40960 | 1:20 | |
| SAdV-30 | <1:20 | 1:1280 | 1:20 | |
| SAdV-37 | <1:20 | 1:320 | 1:20 | |
| SAdV-39 | <1:20 | 1:320 | 1:20 | |
| B | SAdV-27 | 1:20 | <1:20 | <1:20 |
| SAdV-28 | <1:20 | <1:20 | 1:40 | |
| SAdV-29 | <1:20 | <1:20 | <1:20 | |
| SAdV-32 | <1:20 | <1:20 | <1:20 | |
| SAdV-35 | <1:20 | <1:20 | 1:20 | |
| C | SAdV-31 | 1:5120 | <1:20 | 1:80 |
| SAdV-40 | <1:20 | <1:20 | 1:40 | |
The anti-adenovirus titers using each of the ape adenovirus isolates shown was determined as described in the Materials and methods. The dilution of the antiserum that reduced infectivity by 50% is shown.